Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug
“With this latest appointment, mifepristone has a new boss but an old problem,” writes Julie F. Kay, founder and CEO of Reproductive Futures.
This item is an automated import from an external feed and has not yet been rewritten into a neutral C-IT-ALL summary. Read the full story at the original source below.
Read the full story at STAT News
Related Coverage